Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES FRESENIUS KABI ONCO. ALKEM LABORATORIES/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 25.0 22.1 112.8% View Chart
P/BV x 6.0 3.1 193.4% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ALKEM LABORATORIES   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
FRESENIUS KABI ONCO.
Mar-13
ALKEM LABORATORIES/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs2,720176 1,545.5%   
Low Rs1,66079 2,115.1%   
Sales per share (Unadj.) Rs697.937.7 1,851.8%  
Earnings per share (Unadj.) Rs96.15.1 1,887.2%  
Cash flow per share (Unadj.) Rs117.36.7 1,744.1%  
Dividends per share (Unadj.) Rs25.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs515.242.5 1,211.1%  
Shares outstanding (eoy) m119.57158.23 75.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.13.4 92.9%   
Avg P/E ratio x22.825.0 91.2%  
P/CF ratio (eoy) x18.718.9 98.7%  
Price / Book Value ratio x4.33.0 142.1%  
Dividend payout %26.00-   
Avg Mkt Cap Rs m261,87920,135 1,300.6%   
No. of employees `00014.31.2 1,244.0%   
Total wages/salary Rs m15,055703 2,140.9%   
Avg. sales/employee Rs Th5,822.65,176.2 112.5%   
Avg. wages/employee Rs Th1,050.5610.4 172.1%   
Avg. net profit/employee Rs Th802.0699.6 114.6%   
INCOME DATA
Net Sales Rs m83,4445,963 1,399.4%  
Other income Rs m1,04218 5,790.0%   
Total revenues Rs m84,4865,981 1,412.6%   
Gross profit Rs m14,7341,430 1,030.3%  
Depreciation Rs m2,528258 980.1%   
Interest Rs m651-26 -2,502.3%   
Profit before tax Rs m12,5981,216 1,035.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,105342 322.9%   
Profit after tax Rs m11,493806 1,426.1%  
Gross profit margin %17.724.0 73.6%  
Effective tax rate %8.828.1 31.2%   
Net profit margin %13.813.5 101.9%  
BALANCE SHEET DATA
Current assets Rs m54,9605,102 1,077.3%   
Current liabilities Rs m32,4332,385 1,359.7%   
Net working cap to sales %27.045.6 59.3%  
Current ratio x1.72.1 79.2%  
Inventory Days Days80150 53.0%  
Debtors Days Days72113 63.7%  
Net fixed assets Rs m32,7105,148 635.4%   
Share capital Rs m239158 151.1%   
"Free" reserves Rs m61,3686,556 936.1%   
Net worth Rs m61,6076,732 915.2%   
Long term debt Rs m1,592952 167.2%   
Total assets Rs m99,43310,388 957.2%  
Interest coverage x20.4-45.8 -44.5%   
Debt to equity ratio x00.1 18.3%  
Sales to assets ratio x0.80.6 146.2%   
Return on assets %12.27.5 162.7%  
Return on equity %18.712.0 155.8%  
Return on capital %21.014.6 143.6%  
Exports to sales %19.174.5 25.6%   
Imports to sales %3.024.8 12.0%   
Exports (fob) Rs m15,9174,441 358.4%   
Imports (cif) Rs m2,4831,477 168.1%   
Fx inflow Rs m16,0615,298 303.2%   
Fx outflow Rs m2,4831,772 140.1%   
Net fx Rs m13,5783,525 385.2%   
CASH FLOW
From Operations Rs m5,8511,274 459.2%  
From Investments Rs m-7,414-1,204 615.6%  
From Financial Activity Rs m792-196 -403.6%  
Net Cashflow Rs m-731-126 578.9%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 33.1 0.3 11,033.3%  
FIIs % 0.0 9.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 9.1 -  
Shareholders   68,381 42,599 160.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  GLENMARK PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS